Relacorilant shows promise for ovarian cancer treatment#Relacorilant #shows #promise #ovarian #cancer #treatment
Tag: treatment
Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds
Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds#Blood #testguided #treatment…
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment o
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary…
Jasper Therapeutics' SWOT analysis: briquilimab stock potential in urticaria treatment
Jasper Therapeutics' SWOT analysis: briquilimab stock potential in urticaria treatment#Jasper #Therapeutics039 #SWOT #analysis #briquilimab #stock #potential…
Capricor: High-Reward DMD Treatment Bet With Strong Data And Looming FDA Decision
Capricor: High-Reward DMD Treatment Bet With Strong Data And Looming FDA Decision #Capricor #HighReward #DMD #Treatment…
Soil treatment innovation could slash brownfield remediation costs
Clare Thomas, managing director of SMR UK ReBind is a new remediation technology that its developer,…
VOXZOGO shows promise in tibial bowing treatment
VOXZOGO shows promise in tibial bowing treatment#VOXZOGO #shows #promise #tibial #bowing #treatment
LENZ Therapeutics inks deal with Lotus for eye treatment
LENZ Therapeutics inks deal with Lotus for eye treatment#LENZ #Therapeutics #inks #deal #Lotus #eye #treatment
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated…
EU grants full approval to FILSPARI for IgAN treatment
EU grants full approval to FILSPARI for IgAN treatment#grants #full #approval #FILSPARI #IgAN #treatment
KEYTRUDA ® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally
KEYTRUDA ® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free…
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality,…
SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union
SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults…
UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Inva
UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial…
Formosa Pharmaceuticals and Saval Corporation Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain
Formosa Pharmaceuticals and Saval Corporation Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment…
UniQure N.V. (QURE) Soars on FDA Breakthrough Therapy Designation for Huntington’s Disease Treatment
As of this writing, UniQure N.V.’s stock price has surged 35.89% to $12.79 per share after…
Verve Therapeutics: A New Era in Cardiovascular Disease Treatment?
In a major breakthrough, Verve Therapeutics (VERV) has announced positive results from its Heart-2 clinical trial.…
Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies
Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies#Akeso039s #Results #Strengthening…
Soleno Therapeutics: A Breakthrough in Rare Disease Treatment
The biotech world is buzzing with excitement as Soleno Therapeutics (SLNO) has just received FDA approval…
Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts
Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts #Verve #Therapeutics #HeFH…